Payment overview · 2025
General Payments
$4,171.09
257 reported records · 30 companies
Healthcare provider profile · identity verified
Amit Arora, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HUNTSVILLE, AL · NPI 1750598660
Verified facts
What the public records show
CMS Open Payments records show Amit Arora, M.D. received $4,171.09 in general payments during 2025 across 257 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Fycompa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $819.04 | 19.6% | 66 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $482.38 | 11.6% | 46 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $375.92 | 9.0% | 25 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $271.62 | 6.5% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $239.23 | 5.7% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $199.75 | 4.8% | 9 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $180.02 | 4.3% | 11 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $175.76 | 4.2% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $128.70 | 3.1% | 8 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $115.47 | 2.8% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $101.96 | 2.4% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $100.97 | 2.4% | 5 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $99.95 | 2.4% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $97.10 | 2.3% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $93.53 | 2.2% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $79.60 | 1.9% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $79.32 | 1.9% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $71.01 | 1.7% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$70.75 | 1.7% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$68.93 | 1.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $67.64 | 1.6% | 4 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $60.21 | 1.4% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.08 | 1.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.93 | 0.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.75 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.78 | 0.5% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.06 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.34 | 0.4% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $16.79 | 0.4% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.50 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,001.11 | 255 |
| Education | $169.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $469.21 | 36 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $444.64 | 25 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $329.92 | 35 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $329.92 | 35 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $307.28 | 33 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $239.23 | 13 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $212.67 | 14 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $206.77 | 18 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $199.75 | 9 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $175.76 | 8 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $128.70 | 8 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $123.87 | 8 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $113.87 | 5 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $113.87 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $108.19 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $107.17 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $101.64 | 6 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $100.97 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $79.60 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $79.32 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $73.51 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $72.10 | 4 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $71.01 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $70.75 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $67.01 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $66.74 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $60.94 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $52.94 | 3 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $47.55 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $30.22 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $30.22 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $28.89 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $1.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 1096 | 403 |
| Memantine Hcl | Memantine Hcl | 1053 | 369 |
| Levetiracetam | Levetiracetam | 512 | 151 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 488 | 181 |
| Lacosamide | Lacosamide | 422 | 90 |
| Clonazepam | Clonazepam | 274 | 44 |
| Divalproex Sodium | Divalproex Sodium | 218 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 207 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 182 | 65 |
| Primidone | Primidone | 171 | 62 |
| Topiramate | Topiramate | 158 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 38 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 89 | 21 |
| Lamotrigine | Lamotrigine | 76 | 27 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 72 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 25 |
| Oxcarbazepine | Oxcarbazepine | 69 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 55 | 13 |
| Rivastigmine | Rivastigmine | 55 | 17 |
| Zonisamide | Zonisamide | 55 | 15 |
| Gabapentin | Gabapentin | 52 | 13 |
| Lorazepam | Lorazepam | 52 | 49 |
| Prednisone | Prednisone | 40 | 12 |
| Valproic Acid | Valproic Acid | 39 | 14 |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Azathioprine | Azathioprine | 31 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 17 |
| Levetiracetam Er | Levetiracetam | 30 | suppressed |
| Neupro | Rotigotine | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 13 |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Fycompa | Perampanel | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Lamictal | Lamotrigine | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Lamictal Xr | Lamotrigine | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,171.09 · 257 records | ABBVIE INC. | AMPYRA, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, Dysport, EMGALITY, EPIDIOLEX, FYCOMPA, Fintepla, HYQVIA, INBRIJA, INGREZZA, KESIMPTA, LEQEMBI, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, QULIPTA, REXULTI, Rystiggo, SKYCLARYS, Symbravo, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, Xeomin, ZAVZPRET, Zilbrysq | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CATALYST PHARMACEUTICALS, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error